| 4.7 -0.53 (-10.13%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.47 | 1-year : | 7.55 |
| Resists | First : | 5.53 | Second : | 6.47 |
| Pivot price | 4.58  |
|||
| Supports | First : | 3.97 | Second : | 3 |
| MAs | MA(5) : | 4.62 | MA(20) : | 4.47 |
| MA(100) : | 2.92 |
MA(250) : | 1.85 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 52 |
D(3) : | 44.3 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 5.53 | Low : | 0.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRLD ] has closed below upper band by 41.6%. Bollinger Bands are 12.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.23 - 5.26 | 5.26 - 5.29 |
| Low: | 4.42 - 4.46 | 4.46 - 4.49 |
| Close: | 4.64 - 4.7 | 4.7 - 4.75 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Fri, 01 May 2026
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Fri, 01 May 2026
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Thu, 30 Apr 2026
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
Wed, 29 Apr 2026
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
Tue, 28 Apr 2026
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Thu, 23 Apr 2026
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 59.1 (%) |
| Shares Short | 2,320 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.82 |
| Profit Margin | 0 % |
| Operating Margin | -284.6 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | -99.5 % |
| Qtrly Rev. Growth | 41 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -2.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -3.65 |
| PEG Ratio | 0 |
| Price to Book value | 5.66 |
| Price to Sales | 16.94 |
| Price to Cash Flow | -3.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|